QIH Medical Devices Explained

A numerical result can look credible even when its source data or processing has been altered. That is the security problem we focus on in quantitative imaging: protecting the path from image acquisition through analysis to the result a clinician uses.

This article discusses quantitative imaging applications under the QIH label. Manufacturers should not treat that shorthand as a regulatory classification. The device’s intended use and the applicable FDA product-code definition determine the submission path.

Why This Matters

Quantitative imaging software may be Software as a Medical Device (SaMD) or a software component of an imaging system. That distinction matters, but SaMD status alone does not trigger Section 524B of the FD&C Act. Manufacturers must determine whether their product meets the statutory definition of a cyber device.

For applicable devices, we organize the submission evidence around the FDA's premarket cybersecurity guidance, including the February 3, 2026 final guidance: a threat model, an SBOM and supporting vulnerability analysis, security architecture views, independent penetration testing, and a postmarket vulnerability management plan. VEX data can communicate component vulnerability status; it does not replace the underlying assessment.

The clinical consequences should drive the work. Tumor volumes, perfusion parameters, and automated measurements feed clinical decisions. A compromised algorithm or tampered DICOM input can affect treatment, not just confidentiality. The FDA's Guiding Principles for Good Machine Learning Practice and the IMDRF Principles and Practices for Medical Device Cybersecurity provide relevant frameworks for addressing these concerns.

The standards stack includes IEC 62304 for the software lifecycle, ISO 14971 for risk management, AAMI SW96, recognized as 13-131, for security risk management, and IEC 81001-5-1 for the secure software lifecycle. The FDA's SaMD framework applies where the software qualifies. We look for traceability between threats, requirements, controls, test results, and patient harm, not merely a list of standards in the submission.

Understanding the Basics of QIH Devices

Definition and Function of QIH Devices

Before assigning a product code, check the QIH device classification entry against the product’s actual intended use. A product code should not be used as a catch-all term for quantitative imaging.

Quantitative imaging begins with MRI, CT, or ultrasound images. Software then extracts measurements such as tumor size, tissue density, or blood flow. These measurements supplement clinical interpretation and can support disease assessment, treatment monitoring, and surgical planning.

The output is numerical, but it is not automatically correct. Its reliability depends on image quality, acquisition protocols, algorithm performance, and the integrity of the processing path.

History and Development of QIH Devices

Quantitative imaging developed as imaging hardware improved and software became capable of extracting repeatable measurements from images. Clinicians, engineers, and software developers moved these methods from research into clinical workflows.

AI and machine learning continue to expand the analysis methods available. Integration with electronic health records (EHRs) also lets providers compare measurements over time rather than review each examination in isolation.

In research, objective measurements can improve statistical power and reliability when acquisition and analysis methods are controlled. The same requirement applies in clinical use: comparisons only mean something when the underlying measurements are comparable.

Components and Design of QIH Devices

Components of a QIH Device

A quantitative imaging system combines image acquisition, analysis software, and a clinical interface. Standalone software may receive images from separate hardware rather than include the scanner itself.

• Image acquisition hardware: MRI, CT, or ultrasound equipment captures the source images. Image quality and artifacts affect every downstream measurement.
• Software algorithms: Mathematical models and, in some products, machine learning extract measurements such as tumor size or tissue density. Changes to these algorithms require controlled evaluation before release.
• User interface: Clinicians review images, adjust permitted analysis parameters, and interpret results. The interface must make the relationship between the source image and the measurement clear.

We scope security across these components and their connections. Testing only the analysis application leaves unanswered questions about image imports, result exports, service access, and software updates.

Design Principles and Considerations

Accuracy, reliability, usability, and security need to be designed together.

• Image quality: Signal-to-noise ratio, spatial resolution, and contrast sensitivity affect measurement accuracy. Software cannot be assumed to compensate for unsuitable input.
• Automated analysis: Automation can reduce user bias and improve repeatability. Manufacturers still need to define acceptable inputs, operating limits, and how users recognize an unreliable result.
• Data security and privacy: A QIH device's design must include strong security and privacy controls. These include encryption in transit and at rest, access restrictions, secure storage, and integrity protection across hospital-system connections.

This is the part teams skip: turning a security objective into a testable requirement. In the FDA letters we reviewed for our September 2026 MTEC webinar, one letter raised insufficient control detail nine times against nine different controls. Recurring gaps included passwords without a defined policy, TLS 1.2 without cipher suites, and ECDSA without the curve or hash function. For imaging software, “encrypted transfer” is not enough detail to assess the control.

Human factors matter too. Clear controls, readable results, and understandable warnings help reduce fatigue and use errors. Security restrictions should support the clinical workflow without leaving undocumented bypasses.

Applications of QIH Devices in Healthcare

QIH Devices in Diagnostic Procedures

Quantitative imaging supports different clinical tasks depending on the product’s intended use and demonstrated performance.

In oncology, measurements of tumor size, shape, and vascularity can support cancer staging and treatment planning. In neurology, brain-volume measurements can help assess changes associated with neurodegenerative disorders such as Alzheimer’s disease.

In gastroenterology, quantitative imaging methods can assess gastrointestinal motility and function. Systems that capture dynamic changes in the digestive system may support evaluation of conditions such as irritable bowel syndrome and gastroesophageal reflux disease. These are application areas, not capabilities that should be assumed for every imaging product.

Therapeutic Uses of QIH Devices

Quantitative imaging also supports image-guided interventions and minimally invasive procedures. During cardiac catheterization, blood-flow and vessel-diameter measurements can help physicians guide and deploy intravascular devices.

In radiation therapy, measurements of anatomy and tumor characteristics support treatment planning intended to limit exposure to healthy tissue. In orthopedics, joint-motion and alignment data can inform procedures such as joint replacement.

From a security perspective, these uses require more than protecting stored patient information. We need to understand whether altered measurements could change a treatment plan, misdirect an intervention, or delay care.

Advantages of Using QIH Devices

Improving Patient Care with QIH Devices

Quantitative measurements can reduce interobserver variability and improve consistency in disease detection, staging, and monitoring. That benefit depends on suitable inputs and demonstrated device performance, not simply on replacing a visual judgment with a number.

Comparable measurements over time help clinicians assess treatment response and decide whether care needs to change. They can also support resource planning and give patients a clearer basis for discussing treatment choices.

We treat measurement integrity as part of preserving those benefits. A result that has lost its connection to the correct patient, image, or algorithm version should not be treated as trustworthy clinical evidence.

Efficiency and Accuracy of QIH Devices

See also: What Is MedTech? MedTech vs Medical Device vs Life Sciences, CVSS Scoring for Medical Devices: A Complete Walkthrough, and Medical Device Software Development: A Compliance Guide.

Automated analysis can reduce repetitive measurement work and shorten image-review workflows. Clinicians can then spend more time interpreting findings and deciding what they mean for the patient.

Patient-specific measurements also support targeted treatment planning. Efficiency and accuracy remain separate claims, however. Faster processing does not establish clinical accuracy, and security testing does not replace the manufacturer’s performance evaluation.

Challenges and Limitations of QIH Devices

Technical Challenges in QIH Device Usage

Standardization remains a practical obstacle. Different acquisition protocols or algorithm versions can introduce bias and make results difficult to compare across institutions.

Hospital integration adds another layer. Imaging systems must exchange data with electronic medical record systems while preserving patient identity, measurement context, and access restrictions.

Calibration, protocol validation, and performance monitoring are also needed to detect measurement drift. We distinguish that work from security testing: the manufacturer establishes clinical and technical performance, while we assess attack paths and the effectiveness of security controls.

Addressing Limitations and Concerns

The Quantitative Imaging Biomarkers Alliance (QIBA) develops guidance for consistent image acquisition, analysis, and quality control. Following defined methods helps manufacturers and healthcare providers assess reproducibility rather than assume it.

The U.S. Food and Drug Administration evaluates medical devices through the applicable regulatory pathway. Clearance or approval depends on that pathway; the terms are not interchangeable. The assessment considers the evidence needed for the device’s intended use, performance, and risks.

Research into machine learning continues to improve automated analysis and expand potential applications. Each change still needs controlled evaluation. A newer model is not necessarily a safer or more accurate model for every patient population or acquisition setting.

The Future of QIH Devices in Medical Technology

Emerging Trends in QIH Device Technology

The use of artificial intelligence (AI) algorithms is expanding quantitative image analysis. Larger training datasets may improve performance, but manufacturers must also address model integrity and the security of the data used to build and operate the system.

In the FDA letters we reviewed for our September 2026 MTEC webinar, threat models for AI-enabled devices consistently omitted data poisoning, model inversion, and model evasion. Those findings were not specific to quantitative imaging, but they apply directly to the questions an AI-enabled imaging manufacturer should ask. A threat model limited to network access and patient-data theft misses attacks against the model itself.

Portable imaging is another development to watch. Bringing quantitative analysis into point-of-care settings could improve access, but it also changes the operating environment and the assumptions behind access control, connectivity, and updates.

Potential Impact of QIH Devices on Healthcare

Quantitative imaging can extend patient-specific diagnosis, treatment planning, and monitoring across more specialties. Cancer assessment already illustrates the value of repeatable measurements for tracking disease and treatment response.

Integration with telemedicine platforms may support remote review and faster clinician feedback, particularly in rural or underserved areas. That benefit depends on reliable data exchange and clear responsibility for reviewing results.

We expect manufacturers, providers, and regulators to keep working on standardization. Wider deployment makes lifecycle support more important: devices need maintainable software, monitored dependencies, and a working update path throughout their supported life.

QIH devices compared with conventional imaging

This comparison simplifies both categories. Conventional images can also be altered without obvious visual defects. Likewise, the regulatory framing requires a product-specific assessment: standalone software may qualify as SaMD, while Section 524B applicability depends separately on whether it meets the cyber-device definition.

The security distinction worth keeping is the possibility of a plausible but incorrect measurement. We need evidence that protects the input, processing, and output, not just the network connection.

Conclusion

Quantitative imaging gives clinicians measurements that can support diagnosis, treatment planning, and monitoring. Its value depends on repeatability, appropriate clinical use, and confidence that the data and software have not been altered.

For manufacturers, cybersecurity belongs in the design work. Define the system boundaries, identify how an attacker could affect a clinical result, specify controls, and test those controls against the threat model.

Blue Goat Cyber focuses exclusively on medical device cybersecurity, including penetration testing, threat modeling, and premarket and postmarket cybersecurity support. We are a Service-Disabled Veteran-Owned Small Business. Contact us today for cybersecurity help and let us help protect your imaging system and its clinical data.

How Blue Goat approaches this

We start with the architecture, data flows, and intended use. For an imaging system, that means examining how images enter the system, where analysis runs, who can change settings or software, and how results reach clinicians. The threat model sets the security-testing scope.

Our reports connect findings to reproduction evidence, affected controls, remediation recommendations, and patient-safety considerations. We help manufacturers assemble traceable cybersecurity evidence for the FDA; we do not replace their verification and validation activities.

Postmarket planning starts before submission. In our September 17, 2026 secure-by-design workshop in Singapore, we contrasted an SBOM generated once and filed away with an inventory connected to a vulnerability feed, reviewed on a defined cadence, and used in the postmarket risk process. That distinction matters for imaging software whose dependencies remain in service after the original submission.

Learn more about our work at Blue Goat Cyber's Medical Device Penetration Testing.

FAQ

What is a QIH medical device?

This article uses QIH as shorthand for quantitative imaging applications that extract measurements from images such as MRI or CT scans. Manufacturers should verify the applicable FDA product-code definition rather than assume QIH covers every quantitative imaging system.

How do QIH devices improve patient care?

Quantitative imaging can reduce variation in measurements and help clinicians track disease and treatment response. When supported by appropriate performance evidence, those measurements can improve diagnostic consistency and support patient-specific care.

What are the cybersecurity concerns for QIH devices?

We focus on patient-data confidentiality and the integrity of images, analysis software, and results. Relevant controls include input validation, authentication, access restrictions, encryption, protected updates, and traceable output. AI-enabled products also need to address threats against training data and models.

Does the FDA regulate QIH medical devices?

Yes. The FDA regulates products that meet the medical-device definition through the applicable pathway. Manufacturers must assess their obligations under Section 524B and the FDA's premarket cybersecurity guidance, including the February 3, 2026 final guidance. SaMD status alone does not establish that Section 524B applies.

How can QIH devices integrate with existing healthcare systems?

Integration requires compatible interfaces and data formats, correct patient and study association, and secure exchange with electronic medical records (EMRs) and other hospital systems. We recommend including those connections in both the threat model and the security-testing scope.

Related: Medical Device AI Performance Drift